Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies.
Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio of innovative medicines, radiopharmaceutical products and generic pharmaceuticals to best meet these needs. Novartis Group companies employ approximately 125,000 associates (2018) and operate in more than 140 countries around the world.
Novartis Global Drug Development is a leader in development of innovative medications in areas such as cardiometabolic indications, dermatology, immunology, neuroscience, oncology, ophthalmology and respiratory.
Novartis is involved in a large number of IMI1 and IMI2 projects, of which 7 are connected to EU-PEARL (ROADMAP; EPAD, PARADIGM, PREFER, conect4children; LITMUS).